Skip to Main Content

WASHINGTON — A Department of Veterans Affairs committee has declined to approve widespread coverage of a new depression treatment that has generated controversy but also received an express endorsement from President Trump. Instead, the drug was approved on a more limited basis.

Many experts have embraced the medication, which is known as esketamine and is being sold by Johnson & Johnson (JNJ) under the brand name Spravato, as a critical option for patients in dire need of new treatments — particularly because it might work faster than existing antidepressants.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Comments are closed.